

Article

Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study

Annarita Fanizzi ^{1,†} , Domenico Pomarico ^{1,†}, Angelo Paradiso ² , Samantha Bove ³ , Sergio Diotiaiuti ⁴, Vittorio Didonna ¹, Francesco Giotta ⁵, Daniele La Forgia ^{6,*} , Agnese Latorre ⁵, Maria Irene Pastena ⁷, Pasquale Tamborra ¹, Alfredo Zito ⁷, Vito Lorusso ⁵ and Raffaella Massafra ¹

- ¹ Struttura Semplice Dipartimentale di Fisica Sanitaria, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy; a.fanizzi@oncologico.bari.it (A.F.); domenico.pomarico@hotmail.it (D.P.); v.didonna@oncologico.bari.it (V.D.); p.tamborra@oncologico.bari.it (P.T.); r.massafra@oncologico.bari.it (R.M.)
 - ² Oncologia Medica Sperimentale, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy; a.paradiso@oncologico.bari.it
 - ³ Dipartimento di Matematica, Università degli Studi di Bari, 70121 Bari, Italy; s.bove9@studenti.uniba.it
 - ⁴ Struttura Semplice Dipartimentale di Chirurgia, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy; sergiodiotiaiuti@gmail.com
 - ⁵ Unità Operativa Complessa di Oncologia Medica, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy; f.giotta@oncologico.bari.it (F.G.); a.latorre@oncologico.bari.it (A.L.); vitolorusso@me.com (V.L.)
 - ⁶ Struttura Semplice Dipartimentale di Radiologia Senologica, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy
 - ⁷ Unità Operativa Complessa di Anatomia Patologica, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy; m.pastena@oncologico.bari.it (M.I.P.); a.zito@oncologico.bari.it (A.Z.)
- * Correspondence: d.laforgia@oncologico.bari.it; Tel.: +39-080-5555111
- † These authors contributed equally to this work.



Citation: Fanizzi, A.; Pomarico, D.; Paradiso, A.; Bove, S.; Diotiaiuti, S.; Didonna, V.; Giotta, F.; La Forgia, D.; Latorre, A.; Pastena, M.I.; et al. Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study. *Cancers* **2021**, *13*, 352. <https://doi.org/10.3390/cancers13020352>

Received: 20 December 2020
Accepted: 15 January 2021
Published: 19 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Simple Summary: Sentinel lymph node biopsy procedure is time consuming and expensive, but it is still the intra-operative exam capable of the best performance. However, sometimes, surgery is achieved without a clear diagnosis, so clinical decision support systems developed with artificial intelligence techniques are essential to assist current diagnostic procedures. In this work, we evaluated the usefulness of a CancerMath tool in the sentinel lymph nodes positivity prediction for clinically negative patients. We tested it on 993 patients referred to our institute characterized by sentinel lymph node status, tumor size, age, histologic type, grading, expression of estrogen receptor, progesterone receptor, HER2, and Ki-67. By training the CancerMath (CM) model on our dataset, we reached a sensitivity value of 72%, whereas the online one was 46%, despite a specificity reduction. It was found the addition of the prognostic factors Her2 and Ki67 could help improve performances on the classification of particular types of patients.

Abstract: In the absence of lymph node abnormalities detectable on clinical examination or imaging, the guidelines provide for the dissection of the first axillary draining lymph nodes during surgery. It is not always possible to arrive at surgery without diagnostic doubts, and machine learning algorithms can support clinical decisions. The web calculator CancerMath (CM) allows you to estimate the probability of having positive lymph nodes valued on the basis of tumor size, age, histologic type, grading, expression of estrogen receptor, and progesterone receptor. We collected 993 patients referred to our institute with clinically negative results characterized by sentinel lymph node status, prognostic factors defined by CM, and also human epidermal growth factor receptor 2 (HER2) and Ki-67. Area Under the Curve (AUC) values obtained by the online CM application were comparable with those obtained after training its algorithm on our database. Nevertheless, by training the CM model on our dataset and using the same feature, we reached a sensitivity median value of 72%, whereas the online one was equal to 46%, despite a specificity reduction. We found that the addition of the prognostic factors Her2 and Ki67 could help improve performances on the classification of particular types of patients with the aim of reducing as much as possible the false

positives that lead to axillary dissection. As showed by our experimental results, it is not particularly suitable for use as a support instrument for the prediction of metastatic lymph nodes on clinically negative patients.

Keywords: sentinel lymph node; early breast cancer; decision support system; OSNA; clinically negative lymph node; CancerMath

1. Introduction

Cancer diagnosis at the early stages is a crucial step for the prevention of metastatic processes when cells spread from the primary tumor by contiguity, via the blood or the lymphatics, settling in other organs or tissues. This event causes an extremely negative impact on both the course of the disease and the long-term survival, the early detection of the disease spread, and the early treatment through medical or surgical therapy can avoid the negative effects of distant dissemination and restore a good prognosis to the patient. This is particularly true in the context of mammary neoplasms for which the early metastasis main route is the axillary lymphatic node.

Lymph node metastatic positivity highlights a non-lethal spread of the disease, generally treated through surgical dissection [1–4]. A lymph node affected by cancer can present some signs of the disease that can be detected through an ultrasound, Computerized Tomography (CT), or Magnetic Resonance (MR) and, in part, through a clinical exam [5]. Unfortunately, the accuracy of these tests is not absolute and has a large number of false negativity and positivity. In current clinical practice, in the absence of lymph node abnormalities detectable with clinical examination or imaging [1], the guidelines [6] also provide for the removal of the first axillary draining lymph nodes, which are identified by the injection of a radionuclide during surgery for the removal of malignant breast lesions. These lymph nodes are called “sentinel”, identified with a technique known as sentinel node and occult lesion localization (SNOLL), and the subject of a second intra-operative pathological examination known as one-step nucleic acid amplification (OSNA), which currently has sensitivity between 87.5 and 100% and a specificity between 90.5 and 100% [7–10].

Although the OSNA is time consuming and expensive, it is still the intra-operative exam with the highest performance, but sometimes, surgery is achieved without a clear diagnosis. Moreover, large prospective trials have documented sentinel lymph node bioptic complications including allergic reactions, wound infection, seroma, paresthesias, lymphedema, and hematoma [11,12]. For many patients, sentinel lymph node bioptic is more morbid than partial mastectomy, and therefore, axillary surgery is not considered therapeutic in early stage breast cancer [13,14]. In this context, there is a need to evaluate other less invasive and preferably cheaper diagnostic tools that could replace sentinel lymph node bioptic without compromising patient care diagnosis, so Clinical Decision Support Systems (CDSS) developed with artificial intelligence techniques are essential to assist current diagnostic procedures.

The decision support system can be used joint with surgical activity if a high accuracy in predicting sentinel lymph node status is reached. Specifically, the intervention of biopsy could be avoided and the efficiency of surgical intervention could be reduced in terms of time and costs. Among the different proposals in the literature, CancerMath (CM) [15] is an open source cancer web calculator developed to provide support in the clinical outcome prediction for patients affected by breast cancer, melanoma, and renal cells, as well as accurately evaluate the impact of various treatment choices [3,4]. Among the different implemented calculators, CM also allows calculating the probability of having different positive lymph nodes for breast tumors characterized by a certain dimension estimated according to particular prognostic factors such as age, histological type, grading, and the presence of both estrogen and progesterone receptors.

In this work, with the aim of evaluating the usefulness of this tool in the sentinel lymph nodes positivity prediction for clinically negative patients, we first assessed the CM algorithm classification performance on a sample of patients affected by breast cancer referred to our institute. The innovative approach of our work is to train appropriately the CM algorithm on our kind of patients and adapt it to the task to predict sentinel lymph nodes status in clinically negative patients, therefore tendentially with an early stage tumor. We have evaluated the classification results obtained both by considering the same set of prognostic factors used by the online software and by adding other known prognostic factors such as proliferation marker Ki67 and human epidermal growth factor receptor 2 (Her2).

2. Materials and Methods

2.1. Experimental Data

From 2016 to 2018, we have collected the histological outcome of 993 patients of Istituto Tumori “Giovanni Paolo II” of Bari (Italy) who had negative results after both clinical and instrumental examination and had undergone the OSNA procedure. Specifically, we considered the patients who were clinically negative for lymph nodes and did not have suspicious signs in axillary ultrasound, routine examination in the pre-surgical staging phase of the armpit, or they were negative by fine needle aspiration biopsy following the identification of axillary changes on instrumental examination. In Figure 1, we provided a diagram showing the typical processes of the work-up and interventions used in practice for breast cancer patients with clinically negative lymph nodes.




Figure 1. The diagram shows the typical processes of the work-up and interventions used in practice for breast cancer patients with clinically negative lymph nodes.

In our analysis, in addition to the features used by CM software, that is age at diagnosis, histological subtype (ductal, lobular), estrogen receptor expression (ER, Pos/Neg), progesterone receptor expression (PR, Pos/Neg), histological grade (G, Elston-Ellis scale: 1, 2, 3), tumor size (T, measured in mm), and sentinel lymph nodes status (N, Pos/Neg), we used also the cellular marker for proliferation (Ki67, Pos/Neg with cut-off 20%), epidermal growth factor receptor 2 (Her2: negative/positive).

The retrospective observational study was approved by our Institute’s Scientific Board. Before undergoing routine surgery, all patients signed an informed consent form authorizing the use of the removed biological tissue for research purposes according to ethical standards.

2.2. Histological Evaluation Procedure

According to the European guidelines in case of uncertain or suspect clinical or radiological exam of the axillary state, the surgeon decides either to operate a lymph nodes axillary dissection during the surgery or, in absence of suspicion, to proceed with the sentinel lymph nodes biopsy evaluation. The OSNA method is an isothermal procedure

that employs a nucleic acids rapid amplification technology in order to detect the mRNA expression level in the cytokeratin 19, which is an epithelial cells marker not normally present in lymph node tissue. The OSNA system is in compliance with the European directive about the in vitro diagnostic 98/79/CE (CE-IVD), and it is therefore approved for diagnostic purposes throughout Europe.

The histological examination was performed through multiple sampling with 14–16 G core biopsy under ultrasound guidance. The picked whips were inserted in a container with formalin and sent on the same day to the Pathological Anatomy Department. Histological grade and expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 antigen associated with cell proliferation were determined by immunohistochemical analysis carried out by the subspecialty department of breast disease in our institute. Specifically, for each sample, the expression of ER, PR, and Ki67 were valued in percentage terms. Tumor grade G was defined by the Elston–Ellis modification of the Scarff–Bloom–Richardson grading system on a three-grade scale. Specifically, based on the duct structures, the size and shape of the nucleus in the tumor cells and mitotic rate were assessed, and a lesion can be of grade G1 (low grade), G2 (intermediate grade) or G3 (high grade), where a lower grade indicates a better prognosis [16].

2.3. Algorithm Cancer Math

The CancerMath (CM) algorithm implemented on an online free platform [15] and with an open source code aims at modeling the diffusion of cancer cells belonging to the primary lesion [3,4]. CM estimates the probability of lymph node involvement on the basis of prognostic factors such as cancer mass diameter measurement, age, histological type, grading, and estrogen and progesterone receptors.

Compared to the online CM algorithm [15], the probability of positive sentinel lymph nodes is estimated using the following model:

$$L_n \approx 1 - \exp(-Q_n \prod g_i D^Z) \quad (1)$$

where D is the diameter of the primary tumor mass, g_i are the parameters associated with each sub-category of the prognostic factors considered, such as age, grading, histological type, ER (Pos/Neg), PR (Pos/Neg), Q_n is an interpolation parameter referred to the whole population, while Z is a parameter set equal to 1 when studying lymph node involvement, as indicated by the authors [3,4]. In practice, the probability estimate is a function of the population diameters whose parameters Q_n and g_i are previously estimated on a training sample.

Specifically, the value of Q_n and the parameters are determined through a training procedure starting from the average probability of spread of a tumor cell toward the sentinel lymph nodes, which is estimated in a sub-sample of W patients corresponding to each of the ranges of the above prognostic factors, and the training procedure is developed in two phases. In the first phase, the Q_n value is calculated on the entire sample of the reference population by equating the average probability of spread of a tumor cell with the observed statistical frequency of positive lymph nodes in the entire population, in a numerical way, assuming in this first phase that the parameters g_i are all equal to 1.

Subsequently, in the second phase, the newly determined value of Q_n is fixed in each sub-population, and one proceeds in the same way for each range of values of the prognostic factors, with the estimation of the probability function of only the diameters of the sub-populations, which produce measures corresponding to the impact of the prognostic factor as a cause statistically independent of the others.

This model is included in a broader framework of predictive tools, and the web-calculator generally returns the probability of lymph node involvement estimated by (1) with respect to the characteristics entered and the estimated parameters of the training dataset. In case of missing data, the parameter corresponding to the feature is equal to 1 so that production is not compromised.

Using the online platform, the parameters are pre-set and estimated on the training population used by the authors, which is heterogeneous by type of patients and characteristics of the mammary tumors considered compared to those of our interest.

Starting from the CM algorithm, we investigated three other classifiers, the first one obtained by retraining the same model on our dataset, obtaining therefore new values for the parameters Q_n and g_i (A), and the other ones obtained by adding either proliferation marker Ki67 (Pos/Neg) (B), human epidermal growth factor 2 Her2 (Pos/Neg) (C), or both (D).

2.4. Performance Evaluation

We have performed the importance feature analysis on 80% of the sample that is on 795 clinically negative patients. Specifically, the training set of hold-out validation sampling was made up of 640 cases with negative sentinel lymph node (control cases) and 155 cases, it was positive at post-operative histological survey. In contrast, the hold-out validation sampling was made up of 145 and 53 cases with negative and positive sentinel lymph node, respectively.

The CM performances computed using the online software, thus using the model parameters g_i set by the calculator, were compared with the ones obtained by retraining the classification algorithm CM on our dataset with the same features (classifier A) and then adding separately the two prognostic factors Her2 (classifier B) and Ki67 (classifier C), or both these features (classifier D).

The classification performances of CM on line application and A, B, C, and D models both on hold-out training and the test set are evaluated in terms of Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve and, once we identified the optimal threshold by Youden's index on ROC curves [17], we have also calculated:

$$\text{Accuracy} = (TP + TN) / (TP + TN + FP + FN) \quad (2)$$

$$\text{Sensitivity} = TP / (TP + FN) \quad (3)$$

$$\text{Specificity} = TN / (TN + FP) \quad (4)$$

where TP and TN stand for True Positive (number of cases with positive sentinel lymph correctly classified) and True Negative (number of cases with negative sentinel lymph correctly classified), while FP (number of negative cases identified as positive) and FN (number of positive cases identified as negative) are False Positive and False Negative ones, respectively.

Specifically, the prediction performances of A, B, C, and D models obtained on the hold-out training set are evaluated on 100 ten-fold cross-validation rounds and summarized in terms of median, 1st, and 3rd quartile.

3. Results

Characteristics of the patients are summarized in Table 1. A total of 993 patients aged between 23 and 92 years (with a median, first, and third quartile of 56, 48, and 66 years, respectively) were included in the study. In total, 208 of these were positive on histological examination of the sentinel lymph nodes, while 785 were negative.

Table 2 shows the performances statistics obtained on 100 ten-fold cross-validation rounds in order to collect statistics on the performances provided on the basis of the patient variation in the training set and in the validation one. The CM calculator reaches a specificity of 73.6% and 75.2% but a sensitivity of 46.4% and 41.5% on the hold-out training and test sets, respectively. By training the same algorithm in cross-validation with the same features on the hold-out training set, there is a countertrend in performances: the sensitivity increases to 72.3% and 73.6%, while the specificity drops to 54.2% and 43.4% in the hold-out training and test sets, respectively.

Table 1. Absolute (percentage) distribution of patients with positive lymph nodes according to considered prognostic factors.

Prognostic Factor	N. Patients (%)	N. Positive (% of Total)	Prognostic Factor	N. Patients (%)	N. Positive (% of Total)
Overall	993 (100%)	208 (20.95%)	ER ($\geq 1\%$)		
Age			negative	121 (12.19%)	16 (13.22%)
21–30	2 (0.20%)	0 (0%)	positive	872 (87.81%)	192 (22.02%)
31–40	61 (6.14%)	14 (22.95%)	PR ($\geq 1\%$)		
41–50	258 (25.98%)	73 (28.29%)	negative	234 (23.54%)	39 (16.67%)
51–60	292 (29.41%)	62 (21.23%)	positive	759 (80.06%)	169 (22.27%)
61–70	239 (24.07%)	39 (16.32%)	Ki67 ($\geq 20\%$)		
71–80	126 (12.69%)	18 (14.26%)	negative	664 (66.87%)	132 (19.87%)
81–90	14 (1.41%)	2 (14.28%)	positive	329 (33.13%)	76 (23.10%)
>90	1 (0.10%)	0 (0%)	HER2		
Diameter (mm)			negative	870 (87.61%)	180 (20.69%)
T1 (≤ 20)	748 (75.33%)	130 (17.38%)	positive	117 (11.78%)	26 (22.22%)
T2 ($>20, \leq 50$)	231 (23.26%)	69 (29.87%)	unknown	6 (0.61%)	2 (33.33%)
T3 (>50)	14 (1.41%)	9 (64.29%)	Grading		
Histologic type			G1	106 (10.68%)	32 (30.19%)
ductal	718 (72.31%)	129 (17.97%)	G2	176 (17.72%)	47 (26.70%)
lobular	64 (6.44%)	17 (26.56%)	G3	115 (11.58%)	30 (26.09%)
unknown	211 (21.25%)	62 (29.38%)	unknown	596 (60.02%)	99 (16.61%)

Table 2. Classification performances obtained by online CancerMath (CM) application and by training A, B, C, and D models on our dataset. The prediction performance of A, B, C, and D models obtained on the hold-out training set were evaluated on 100 ten-fold cross-validation rounds and summarized in terms of median, 1st, and 3rd quartile.

Model	Performance Measure	Hold-Out Training Set	Hold-Out Test Set
CM on line	AUC (%)	64.7	68.6
	Acc (%)	68.3	66.2
	Sens (%)	46.4	41.5
	Spec (%)	73.6	75.2
CM features (A)	AUC (%)	68.0 (67.6–68.3)	68.6
	Acc (%)	57.6 (55.4–66.2)	51.5
	Sens (%)	72.3 (58.4–76.7)	73.6
	Spec (%)	54.2 (50.5–67.9)	43.4
CM features + Her2 (B)	AUC (%)	67.6 (67.2–68.0)	67.8
	Acc (%)	56.4 (55.1–62.6)	52.0
	Sens (%)	74.2 (62.9–77.7)	73.6
	Spec (%)	52.1 (50.1–63.7)	42.1
CM features + Ki67 (C)	AUC (%)	67.4 (67.0–67.7)	68.0
	Acc (%)	56.4 (55.2–63.5)	50.5
	Sens (%)	74.2 (61.6–76.5)	69.8
	Spec (%)	52.0 (50.2–64.3)	45.5
CM features + Ki67 + HER2 (D)	AUC (%)	64.1 (63.8–64.6)	65.4
	Acc (%)	58.5 (56.1–61.3)	53.8
	Sens (%)	68.1 (52.5–60.6)	70.4
	Spec (%)	55.9 (63.2–71.9)	48.3

Since the grading is missing information for some patients of our dataset, as well as the histological type, we trained the model used by CM by including factors related to them—that is Ki67 and Her2, respectively (p -values Chi-square test < 0.05) [18–20]. However, the inclusion of these features characterizing the tumor can replace any missing information. However, the entering of this information, separately or together, does not significantly improve the general performances.

The score thresholds selected by using Youden's test on the hold-out training set match for the classifiers A, B, C, and D, and are equal to 0.15, while concerning the online algorithm, the threshold is equal to 0.32. This difference is significant due to the non-representativeness of the sample used to train the online web calculator compared to that of our study. These score thresholds are used to classify the subjects of the hold-out test set.

In order to assess whether the model responds better in particular types of patients than others, in Table 3, we have reported the performances obtained by different trained classifiers performances. We have considered patient sub-samples characterized by either particular prognostic factors or clinical conditions, such as diameter of the primary cancer mass ($T1 \leq 20$ mm, $20 \text{ mm} < T2 \leq 50$ mm), age, grading molecular subtypes by summarizing Er, PR, ki67, and HER2. The performances measured on the result of the CM retrained on our data but with the same features are always greater than the performances of the online CM in terms of sensitivity, except for both patients with tumors having a dimension ranging from 20 to 50 mm (T2) and patients with an age between 45 and 60 years, probably in the menopausal period, for which the online CM reaches a sensitivity of 78% and 77%, respectively.

Table 3. Median values of classifiers performances evaluated on the hold-out training set in stratification sub-samples.

Characteristic	Sample Size (Pos)	CM on Line		A (CM)	
		Sens	Spec	Sens	Spec
Overall	795 (155)	42%	79%	72%	54%
T1	595 (98)	61%	57%	70%	60%
T2	188 (49)	78%	35%	61%	51%
Age ≤ 45	134 (34)	21%	94%	59%	59%
45 < Age ≤ 60	369 (82)	77%	42%	70%	58%
Age > 60	292 (39)	46%	86%	64%	63%
G1	43 (15)	33%	82%	33%	82%
G2	96 (24)	58%	75%	88%	39%
G3	61 (17)	82%	50%	88%	36%
Luminal A	482 (90)	64%	57%	77%	52%
Luminal B	202 (48)	69%	56%	83%	45%
Her2 pos	37 (6)	50%	74%	50%	77%
Triple negative	68 (9)	89%	31%	100%	20%

In order not to burden the discussion, we have not included the performance details for the classifiers obtained by adding Ki67 and Her2, or both. In general terms, the median performances observed in the population sub-samples obtained by the retrained classifiers on our data, both with the same features used by the online CM and by including either Ki67 or Her2, are comparable in terms of sensitivity and specificity, emphasizing once again the absence of a significant difference. However, it should be noted that by retraining the classifier and including the factor Ki67, the sensitivity relative to the tendentially menopausal age patients increases to 83%, while the sensitivity of the more aggressive tumors, with grading 3 and triple negative, increases by including the Her2 factor (94% and 100% respectively), but always at the expense of a loss in specificity.

4. Discussion

The use of CDSS for the personalized medicine represents the way to preserve the patients' safety, the care quality, and its efficiency [21]. Especially in the diagnosis of cancers as complex diseases, the introduction of a multifactorial analysis that is able to exploit both the information associated with the presence of particular biomarkers and the one resulting from the genic expression allows us to obtain optimal chemotherapeutic treatments plans [22].

The tools provided by the use of machine learning are able to deal with the complexity associated with this type of diseases in the mutual optimization of several factors [23,24],

which is the reason why different platforms are being developed in order to share not only the simple data but also the same algorithms [25].

In the particular case of pre-operative identification of lymph node metastases in breast tumors for clinically negative patients, the prediction of the lymph node status by means of less invasive procedures than the OSNA procedure is an important task that would also allow us to reduce the relative time and cost of the intervention. For this reason, the development of methods able to detect this condition during the first phases of the cancer mass growth is really important [26].

Concerning the clinical application, the OSNA procedure currently offers a sensitivity range equals to 87.5–100%, while regarding the specificity, the range is equal to 90.5–100% [8–10]; therefore, the new algorithms with this purpose have to meet or exceed these thresholds.

The relationship between clinical and genetic data leads to focus also on the biomarkers of the receptors (hormonal) estrogen ER and progesterone PR, the proliferation markers Ki67, and the human epidermal growth factor 2 Her2. Starting with these ones, it is possible to define molecular sub-types that are a fundamental breast cancer characterization based on the genetic expression profile [27–29]. Immunohistochemical expression on the basis of the St. Gallen sub-types [28] allowed us to verify a statistically significant association between the clinically negative state and the subtype luminal A, as well as the subtype Her2-positive being associated to a clinically positive state. In our analysis, we focused only on the first of these categories, namely clinically negative patients [2].

The online CM algorithm studied in this work aims to estimate the probability of having positive lymph nodes for breast cancers, although this probability computation is included in a broader framework regarding the oncological patient survival analysis. The algorithm estimates this probability on the basis of prognostic factors such as cancer mass dimension, age, histological type, grading, estrogen and progesterone receptors. The online software has been trained on different tumor kinds characterized by various sizes of the primary lesion, which is a parameter that plays a primary role in the probability computation. For this reason, the online algorithm performance shows disputable results on our dataset composed of clinically negative patients, therefore with low values of the tumor diameter. Even though the new training increases the sensitivity, the algorithm presented in this work still does not reach sufficient values for the case of small diameter tumors. In particular, sub-samples characterized by more aggressive tumors, such as the high tumor grade and triple negative one, or for menopausal age one, the addition of the prognostic factors, Her2 and Ki67, respectively, can help in increasing sensitivity, even though for sparsely populated sub-samples. Anyway, the performances do not allow a clinical application of the algorithm.

It should be emphasized that a limitation of our study is the lack of a large amount of data relating to grading and histology. However, the platform itself provides for the possibility of entering “unknown data” as an answer, and the model is trained to deal with this circumstance. Nonetheless, we also evaluated the insertion of features known to characterize the tumor and related to them without obtaining a significant improvement in performance.

The CM performances have been validated in different studies [30–32], but only in [31] did the authors consider the package related to the lymph node involvement probability computation on a sample of the population of the South-Eastern Asia. Specifically, in [31], the authors highlight that the median probability estimated by CM of having a lymph node involvement is equal to 40.6%, underestimating the real one of the samples under study (43.6%).

We want to underline that despite the code being open source, in the works in which the CM algorithm was validated on other populations, the model was not re-trained on the population of interest to estimate new parameters, as we did in this work.

On the basis of the state-of-art, most works propose non-sentinel lymph node status predictive models by using features of a different nature, including nomograms of clinical

and pathologic variables [33–37]. On the other hand, the literature is poor in studies aimed at the development of sentinel lymph nodes predictive models [38–40]. In [38], the author proposed a prediction model for sentinel lymph node metastasis using genetic features, tumor size, and lymph vascular invasion in ER-positive and HER2-negative (ER+/HER2−) breast cancers, thus reaching an AUC value of 0.883. In [39], the authors developed a prediction model for detecting the negativity of sentinel lymph node in order to reduce additional axillary surgery in patients with ductal carcinoma in situ upstaged to invasive cancer. They reached an AUC value of 75% using histological features, such as multifocality, size, histologic type, grade, lymph vascular invasion, hormone receptor expression, and Ki-67 level.

It should be noted that the estimate of the sentinel lymph nodes positivity probability achieves the best performances when supported by radiomic analysis. The information coming from imaging, such as diffusion wavelet and dynamic contrast-enhanced magnetic resonance imaging (DWI and DCE-MRI), is exploited using logistic regression models [41], convolution neural networks [42], and least absolute shrinkage and selecting operator [43,44]. Nevertheless, clinically negative patients are not generally subjected to magnetic resonance imaging, but only to first-level instrumental investigations such as mammography and ultrasound. Radiomic studies on these imaging categories aimed at the prediction of the lymph node involvement are sparse, unlike the many studies on the detection and characterization of breast lesions [45–52]. In recent studies, both histopathologic and radiomic features are jointly used to predict the probability lymph node metastasis, thus obtaining highly performing results [5,53]. These better performances encourage us to face the lymph node state problem by using both other clinical data types (as multifocality, lymph vascular invasion, and tumor location [54]) and information coming from other sources, such as genetics and above all radiomics.

5. Conclusions

In this work, we presented the prediction results of sentinel lymph node positivity obtained using the CancerMath software. As showed by our experimental results, it is not particularly suitable for use as a support instrument for the prediction of metastatic lymph nodes on clinically negative patients, not even re-training it on the sample of our patients' kind. However, some food for thought emerged for other works in the future: the addition of the prognostic factors Her2 and Ki67 could help improving performances on the classification of particular types of patients. Furthermore, harmonizing the clinical data with the ones obtained from the other information sources, such as radiomics and genetics [38], will be the aim of our future works [24,44,54]. By achieving high levels of accuracy, the use of such a support system would make it possible to avoid both the sentinel lymph node procedure, by reducing time and costs of surgeries, and also unnecessary axillary dissections for particular types of cancers [40].

Author Contributions: Conceptualization, A.F., D.P., S.D., F.G., D.L.F., A.L., and R.M.; data curation, A.F., D.P., A.P., M.I.P., A.Z., and R.M.; formal analysis, A.F., D.P., and R.M.; methodology, A.F., D.P., and R.M.; resources, A.P., A.Z., V.L., and R.M.; software, A.F. and D.P.; supervision, R.M., A.L.; writing—original draft, A.F., D.P., S.B., D.L.F., A.L., and R.M.; writing—review and editing, A.F., D.P., A.P., S.B., S.D., V.D., F.G., D.L.F., A.L., P.T., M.I.P., A.Z., V.L. and R.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Scientific Board of Istituto Tumori ‘Giovanni Paolo II’—Bari, Italy.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available because are propriety of Istituto Tumori ‘Giovanni Paolo II’—Bari, Italy.

Acknowledgments: This work was supported by funding from the Italian Ministry of Health “Ricerca Finalizzata 2018”.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. *Consensus per L’irradiazione delle Stazioni Linfonodali Mammary*; Associazione Italiana Radioterapia Oncologica: Milan, Italy, 2016.
2. Diotaiuti, S.; De Summa, S.; Altieri, R.; Dantona, C.; Tommasi, S.; Di Gennaro, M.; Giuseppe, R.; Pastena, M.I.; Argentiero, A.; Zito, F.A.; et al. Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002. *Oncol. Lett.* **2020**, *20*, 2469–2476. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Chen, L.L.; Nolan, M.E.; Silverstein, M.J.; Mihm, M.C.; Sober, A.J.; Tanabe, K.K.; Smith, B.L.; Younger, J.; Michaelson, J.S. The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. *Cancer* **2009**, *115*, 5071–5083. [\[CrossRef\]](#)
4. Michaelson, J.S.; Chen, L.L.; Silverstein, M.J.; Mihm, M.C.; Sober, A.J.; Tanabe, K.K.; Smith, B.L.; Younger, J. How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. *Cancer* **2009**, *115*, 5095–5107. [\[CrossRef\]](#)
5. Qiu, S.-Q.; Zeng, H.-C.; Zhang, F.; Chen, C.; Huang, W.-H.; Pleijhuis, R.G.; Wu, J.-D.; van Dam, G.M.; Zhang, G.-J. A nomogram to predict the probability of axillary lymph node metastasis in early breast cancer patients with positive axillary ultrasound. *Sci. Rep.* **2016**, *6*, 21196. [\[CrossRef\]](#)
6. *Early and Locally Advanced Breast Cancer: Diagnosis and Management*; National Institute for Health and Care Excellence: London, UK, 2018.
7. Tsujimoto, M.; Nakabayashi, K.; Yoshidome, K.; Kaneko, T.; Iwase, T.; Akiyama, F.; Kato, Y.; Tsuda, H.; Ueda, S.; Sato, K.; et al. One-step Nucleic Acid Amplification for Intraoperative Detection of Lymph Node Metastasis in Breast Cancer Patients. *Clin. Cancer Res.* **2007**, *13*, 4807–4816. [\[CrossRef\]](#) [\[PubMed\]](#)
8. Banerjee, S.M.; Michalopoulos, N.V.; Williams, N.R.; Davidson, T.; El Sheikh, S.; McDermott, N.; Tran-Dang, M.-A.; Davison, S.; Keshtgar, M.R. Detailed evaluation of one step nucleic acid (OSNA) molecular assay for intra-operative diagnosis of sentinel lymph node metastasis and prediction of non-sentinel nodal involvement: Experience from a London Teaching Hospital. *Breast* **2014**, *23*, 378–384. [\[CrossRef\]](#) [\[PubMed\]](#)
9. Szychta, P.; Westfal, B.; Maciejczyk, R.; Smolarz, B.; Romanowicz, H.; Krawczyk, T.; Zadrozny, M. Intraoperative diagnosis of sentinel lymph node metastases in breast cancer treatment with onestep nucleic acid amplification assay (OSNA). *Arch. Med. Sci.* **2016**, *12*, 1239–1246. [\[CrossRef\]](#) [\[PubMed\]](#)
10. Fanfani, F.; Monterossi, G.; Ghizzoni, V.; Rossi, E.D.; Dinoi, G.; Inzani, F.; Fagotti, A.; Alletti, S.G.; Scarpellini, F.; Nero, C.; et al. One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer. *PLoS ONE* **2018**, *13*, e0195877. [\[CrossRef\]](#)
11. Krag, D.N.; Anderson, S.J.; Julian, T.B.; Brown, A.M.; Harlow, S.P.; Costantino, J.P.; Ashikaga, T.; Weaver, D.L.; Mamounas, E.P.; Jalovec, L.M.; et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. *Lancet Oncol.* **2010**, *11*, 927–933. [\[CrossRef\]](#)
12. DiSipio, T.; Rye, S.; Newman, B.; Hayes, S. Incidence of unilateral lymphedema after breast cancer: A systematic review and meta-analysis. *Lancet Oncol.* **2013**, *14*, 500–515. [\[CrossRef\]](#)
13. Land, S.R.; Kopeck, J.A.; Julian, T.B.; Brown, A.M.; Anderson, S.J.; Krag, D.N.; Christian, N.J.; Costantino, J.P.; Wolmark, N.; Ganz, P.A. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. *J. Clin. Oncol.* **2010**, *28*, 3929–3936. [\[CrossRef\]](#)
14. Giuliano, A.E.; Hunt, K.K.; Ballman, K.V.; Beitsch, P.D.; Whitworth, P.W.; Blumencranz, P.W.; Leitch, A.M.; Saha, S.; McCall, L.M.; Morrow, M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. *JAMA* **2011**, *305*, 569–575. [\[CrossRef\]](#) [\[PubMed\]](#)
15. CancerMath. Available online: <http://www.lifemath.net/cancer/> (accessed on 1 April 2019).
16. Egner, J.R. AJCC Cancer Staging Manual. *JAMA* **2010**, *304*, 1726–1727. [\[CrossRef\]](#)
17. Youden, W.J. Index for rating diagnostic tests. *Cancer* **1950**, *3*, 32–35. [\[CrossRef\]](#)
18. Trihia, H.; Murray, S.; Price, K.; Gelber, R.D.; Golouh, R.; Goldhirsch, A.; Coates, A.S.; Castiglione-Gertsch, M.; Gusterson, B.A. Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors—A surrogate marker? *Interdiscip. Int. J. Am. Cancer Soc.* **2003**, *97*, 1321–1331. [\[CrossRef\]](#) [\[PubMed\]](#)
19. Weidner, N.; Moore, D.H., II; Vartanian, R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel “paraffin”-reactive MIB1 antibody. *Hum. Pathol.* **1994**, *25*, 337–342. [\[CrossRef\]](#)
20. Hoff, E.R.; Tubbs, R.R.; Myles, J.L.; Procop, G.W. HER2/neu amplification in breast cancer: Stratification by tumor type and grade. *Am. J. Clin. Pathol.* **2002**, *117*, 916–921. [\[CrossRef\]](#) [\[PubMed\]](#)

21. Mazo, C.; Kearns, C.; Mooney, C.; Gallagher, W.M. Clinical Decision Support Systems in Breast Cancer: A Systematic Review. *Cancers* **2020**, *12*, 369. [\[CrossRef\]](#)
22. Kim, Y.Y.; Oh, S.J.; Chun, Y.S.; Lee, W.K.; Park, H.K. Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer. *PLoS ONE* **2018**, *13*, e0200100. [\[CrossRef\]](#)
23. Park, C.; Ahn, J.; Kim, H.; Park, S. Integrative Gene Network Construction to Analyze Cancer Recurrence Using Semi-Supervised Learning. *PLoS ONE* **2014**, *9*, e86309. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Madekivi, V.; Boström, P.; Karlsson, A.; Aaltonen, R.; Salminen, E. Can a machine-learning model improve the prediction of nodal stage after a positive sentinel lymph node biopsy in breast cancer? *Acta Oncol.* **2020**, *59*, 689–695. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Federated Learning Powered by NVIDIA Clara. Available online: <https://developer.nvidia.com/blog/federated-learning-clara/> (accessed on 1 April 2019).
26. Cabioglu, N.; Yazici, M.S.; Arun, B.; Broglio, K.R.; Hortobagyi, G.N.; Price, J.E.; Sahin, A. CCR7 and CXCR4 as Novel Biomarkers Predicting Axillary Lymph Node Metastasis in T1 Breast Cancer. *Clin. Cancer Res.* **2005**, *11*, 5686–5693. [\[CrossRef\]](#) [\[PubMed\]](#)
27. Sørli, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 10869–10874. [\[CrossRef\]](#) [\[PubMed\]](#)
28. Coates, A.S.; Winer, E.P.; Goldhirsch, A.; Gelber, R.D.; Gnant, M.; Piccart-Gebhart, M.; Thürlilmann, B.; Senn, H.-J.; André, F.; Baselga, J.; et al. Tailoring therapies—Improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. *Ann. Oncol.* **2015**, *26*, 1533–1546. [\[CrossRef\]](#) [\[PubMed\]](#)
29. Tay, T.K.Y.; Thike, A.A.; Pathmanathan, N.; Jara-Lazaro, A.R.; Iqbal, J.; Sng, A.S.H.; Ye, H.S.; Lim, J.C.T.; Koh, V.C.Y.; Tan, J.S.Y.; et al. Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer. *Oncotarget* **2018**, *9*, 11619–11630. [\[CrossRef\]](#) [\[PubMed\]](#)
30. Hoveling, L.A.; Van Maaren, M.C.; Hueting, T.; Strobbe, L.J.A.; Hendriks, M.P.; Sonke, G.S.; Siesling, S. Validation of the online prediction model CancerMath in the Dutch breast cancer population. *Breast Cancer Res. Treat.* **2019**, *178*, 665–681. [\[CrossRef\]](#)
31. Miao, H.; Hartman, M.; Verkooijen, H.M.; Taib, N.A.; Wong, H.-S.; Subramaniam, S.; Yip, C.-H.; Tan, E.Y.; Chan, P.; Lee, S.-C.; et al. Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia. *BMC Cancer* **2016**, *16*, 820. [\[CrossRef\]](#)
32. Polchai, N.; Sa-Nguanraksa, D.; Numprasit, W.; Thumrongtaradol, T.; O'Charoenrat, E.; O'Charoenrat, P. A Comparison Between the Online Prediction Models CancerMath and PREDICT as Prognostic Tools in Thai Breast Cancer Patients. *Cancer Manag. Res.* **2020**, *12*, 5549–5559. [\[CrossRef\]](#)
33. Houvenaeghel, G.; Lambaudie, E.; Classe, J.M.; Mazouni, C.; Giard, S.; Cohen, M.; Faure, C.; Charitansky, H.; Rouzier, R.; Darai, E.; et al. Lymph node positivity in different early breast carcinoma phenotypes: A predictive model. *BMC Cancer* **2019**, *19*, 45. [\[CrossRef\]](#)
34. Chen, K.; Liu, J.; Li, S.; Jacobs, L. Development of nomograms to predict axillary lymph node status in breast cancer patients. *BMC Cancer* **2017**, *17*, 561. [\[CrossRef\]](#)
35. Ahn, S.K.; Kim, M.K.; Kim, J.; Lee, E.; Yoo, T.-K.; Lee, H.-B.; Kang, Y.J.; Kim, J.; Moon, H.-G.; Chang, J.M.; et al. Can We Skip Intraoperative Evaluation of Sentinel Lymph Nodes? Nomogram Predicting Involvement of Three or More Axillary Lymph Nodes before Breast Cancer Surgery. *Cancer Res. Treat.* **2017**, *49*, 1088–1096. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Bonsang-Kitzis, H.; Mouttet-Boizat, D.; Guillot, E.; Feron, J.-G.; Fourchette, V.; Alran, S.; Pierga, J.-Y.; Cottu, P.; Lerebours, F.; Stevens, D.; et al. Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers. *PLoS ONE* **2017**, *12*, e0169962. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Balachandran, V.P.; Gonen, M.; Smith, J.J.; DeMatteo, R.P. Nomograms in oncology: More than meets the eye. *Lancet Oncol.* **2015**, *16*, e173–e180. [\[CrossRef\]](#)
38. Okuno, J.; Miyake, T.; Sota, Y.; Tanei, T.; Kagara, N.; Naoi, Y.; Shimoda, M.; Shimazu, K.; Kim, S.J.; Noguchi, S. Development of Prediction Model Including MicroRNA Expression for Sentinel Lymph Node Metastasis in ER-Positive and HER2-Negative Breast Cancer. *Ann. Surg. Oncol.* **2021**, *28*, 310–319. [\[CrossRef\]](#) [\[PubMed\]](#)
39. Bevilacqua, J.L.B.; Kattan, M.W.; Fey, J.V.; Cody, H.S., III; Borgen, P.I.; Van Zee, K.J. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. *J. Clin. Oncol.* **2007**, *25*, 3670–3679. [\[CrossRef\]](#)
40. Yoo, T.K.; Kim, S.J.; Lee, J.; Lee, S.B.; Lee, S.J.; Park, H.Y.; Park, H.K.; Chae, B.J.; Eom, Y.H.; Kim, H.S.; et al. A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged from Ductal Carcinoma in Situ. *Clin. Breast Cancer* **2020**, *20*, e281–e289. [\[CrossRef\]](#)
41. Dong, Y.; Feng, Q.; Zhouyang, L.; Lu, Z.; Deng, C.; Zhang, L.; Lian, Z.; Liu, J.; Luo, X.; Pei, S.; et al. Preoperative prediction of sentinel lymph node metastasis in breast cancer based on radiomics of T2-weighted fat-suppression and diffusion-weighted MRI. *Eur. Radiol.* **2018**, *28*, 582–591. [\[CrossRef\]](#)
42. Luo, J.; Ning, Z.; Zhang, S.; Feng, Q.; Zhang, Y. Bag of deep features for preoperative prediction of sentinel lymph node metastasis in breast cancer. *Phys. Med. Biol.* **2018**, *63*, 245014. [\[CrossRef\]](#)
43. Liu, M.; Mao, N.; Ma, H.; Dong, J.; Zhang, K.; Che, K.; Duan, S.; Zhang, X.; Shi, Y.; Xie, H. Pharmacokinetic parameters and radiomics model based on dynamic contrast enhanced MRI for the preoperative prediction of sentinel lymph node metastasis in breast cancer. *Cancer Imaging* **2020**, *20*, 1–8. [\[CrossRef\]](#)

-
44. Liu, J.; Sun, D.; Chen, L.; Fang, Z.; Song, W.; Guo, D.; Ni, T.; Liu, C.; Feng, L.; Xia, Y.; et al. Radiomics analysis of dynamic contrast-enhanced magnetic resonance imaging for the prediction of sentinel lymph node metastasis in breast cancer. *Front. Oncol.* **2019**, *9*, 980. [[CrossRef](#)]
 45. Fanizzi, A.; Basile, T.M.A.; Losurdo, L.; Bellotti, R.; Bottigli, U.; Dentamaro, R.; Didonna, R.; Fausto, A.; Massafra, R.; Moschetta, M.; et al. A Machine Learning Approach on Multiscale Texture Analysis for Breast Microcalcification Diagnosis. *BMC Bioinform.* **2020**, *21*, 91. [[CrossRef](#)] [[PubMed](#)]
 46. Fanizzi, A.; Basile, T.M.A.; Losurdo, L.; Bellotti, R.; Bottigli, U.; Campobasso, F.; Didonna, V.; Fausto, A.; Massafra, R.; Tagliafico, A.; et al. Ensemble Discrete Wavelet Transform and Gray-Level Co-Occurrence Matrix for Microcalcification Cluster Classification in Digital Mammography. *Appl. Sci.* **2019**, *9*, 5388. [[CrossRef](#)]
 47. Losurdo, L.; Fanizzi, A.; Basile, T.M.A.; Bellotti, R.; Bottigli, U.; Dentamaro, R.; Didonna, V.; Lorusso, V.; Massafra, R.; Tamborra, P.; et al. Radiomics Analysis on Contrast-Enhanced Spectral Mammography Images for Breast Cancer Diagnosis: A Pilot Study. *Entropy* **2019**, *21*, 1110. [[CrossRef](#)]
 48. Fanizzi, A.; Losurdo, L.; Basile, T.M.A.; Bellotti, R.; Bottigli, U.; Delogu, P.; Diacono, D.; Didonna, V.; Fausto, A.; Lombardi, A.; et al. Fully Automated Support System for Diagnosis of Breast Cancer in Contrast-Enhanced Spectral Mammography Images. *J. Clin. Med.* **2019**, *8*, 891. [[CrossRef](#)] [[PubMed](#)]
 49. Basile, T.M.A.; Fanizzi, A.; Losurdo, L.; Bellotti, R.; Bottigli, U.; Dentamaro, R.; Didonna, V.; Fausto, A.; Massafra, R.; Moschetta, M.; et al. Microcalcification Detection in Full-Field Digital Mammograms: A Fully Automated Computer-Aided System. *Phys. Med.* **2019**, *64*, 1–9. [[CrossRef](#)] [[PubMed](#)]
 50. Basile, T.M.A.; Fanizzi, A.; Losurdo, L.; Bellotti, R.; Tangaro, S.; La Forgia, D.; Didonna, V.; Massafra, R.; Tamborra, P.; Moschetta, M.; et al. Hough transform for clustered microcalcifications detection in full-field digital mammograms. *Appl. Digit. Image Process.* **2017**, *10396*, 41. [[CrossRef](#)]
 51. Losurdo, L.; Fanizzi, A.; Basile, T.M.A.; Bellotti, R.; Bottigli, U.; Dentamaro, R.; Didonna, V.; Fausto, A.; Massafra, R.; Monaco, A.; et al. A Combined Approach of Multiscale Texture Analysis and Interest Point/Corner Detectors for Microcalcifications Diagnosis. *Lect. Notes Comput. Sci.* **2018**, *1*, 302–313. [[CrossRef](#)]
 52. La Forgia, D.; Fanizzi, A.; Campobasso, F.; Bellotti, R.; Didonna, V.; Lorusso, V.; Moschetta, M.; Massafra, R.; Tamborra, P.; Tangaro, S.; et al. Radiomic Analysis in Contrast-Enhanced Spectral Mammography for Predicting Breast Cancer Histological Outcome. *Diagnostics* **2020**, *10*, 708. [[CrossRef](#)]
 53. Yang, J.; Wang, T.; Yang, L.; Wang, Y.; Li, H.; Zhou, X.; Zhao, W.; Ren, J.; Li, X.; Tian, J.; et al. Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Using Mammography-Based Radiomics Method. *Sci. Rep.* **2019**, *9*, 1–11. [[CrossRef](#)]
 54. Desai, A.A.; Hoskin, T.L.; Day, C.N.; Habermann, E.B.; Boughie, J.C. Effect of Primary Breast Tumor Location on Axillary Nodal Positivity. *Ann. Surg. Oncol.* **2018**, *25*, 3011–3018. [[CrossRef](#)]